Trial reportJournal of the American Heart Association2026
Prognostic Value of Angiographic Microcirculatory Resistance After Coronary Intervention: Insights From the FAVOR III China Trial.
Trial report in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03656848 (Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous InterVention in Patients With cORonary Artery Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous InterVention in Patients With cORonary Artery Disease (The FAVOR III China Study)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA novel computational angiographic microcirculatory resistance (AMR) derived from a single angiographic view presents a feasible alternative to the pressure wire-based index of microcirculatory resistance. However, its prognostic significance in patients undergoing percutaneous coronary intervention (PCI) remains insufficiently established.
methodsThis is a post hoc analysis of 3404 patients undergoing PCI from the FAVOR III China (Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous Intervention in Patients With Coronary Artery Disease) trial. Pre- and post-PCI AMR were measured in target vessels, with percentage change in AMR before and after PCI calculated as (100×[post-PCI AMR-pre-PCI AMR]/pre-PCI AMR). The primary model used was the log-rank test, and the proportional hazards model was also used to assess the association between AMR and the 3-year risk of major adverse cardiac events, defined as a composite of all-cause death, myocardial infarction, or ischemia-driven revascularization.
resultsPatients with percentage change in AMR before and after PCI ≥85 (23.7%) versus <85 (76.3%) had comparable baseline characteristics but received more and longer stents per patient. Overall major adverse cardiac events risk was similar between groups (14.8% versus 12.4%; hazard ratio [HR], 1.18 [0.95-1.45]; log-rank
conclusionsIn patients undergoing PCI from the FAVOR III China population, significant AMR elevation (percentage change in AMR before and after PCI ≥85) in target vessels alone did not predict outcomes, but in the subgroup with post-PCI AMR ≥250 it identified patients at increased 3-year cardiovascular risk. REGISTRATION: https://www.clinicaltrials.gov; Unique identifier: NCT03656848.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.